Maze's Kidney Drug Data Shows Promise, But Fails to Impress Wall Street

SOUTH SAN FRANCISCO, Calif. – March 25, 2026 – Maze Therapeutics today unveiled what it described as positive and promising data for its experimental kidney drug, MZE829, offering a potential new weapon against a devastating genetic disease. The company announced that its Phase 2 HORIZON trial demonstrated the first clinical proof-of-concept for the drug in patients with APOL1-mediated kidney disease (AMKD), a condition that disproportionately affects people of African ancestry and often leads to rapid kidney failure.

Despite the company highlighting clinically meaningful results, the news was met with a turbulent reception on Wall Street. Maze's stock (Nasdaq: MAZE) plummeted nearly 30% in morning trading, signaling a sharp disconnect between the scientific milestone and investor sentiment. The reaction casts a spotlight on the intense competition in the field and the high-stakes battle to deliver a first-in-class treatment for a major unmet medical need.

Targeting a Genetic Scourge

APOL1-mediated kidney disease is driven by high-risk variants in the APOL1 gene. These genetic variants, while thought to have evolved to protect against certain parasites in Africa, put carriers at a significantly higher risk of developing chronic kidney disease that progresses rapidly to end-stage kidney disease and the need for dialysis or transplant. It is estimated to affect over one million people in the United States alone.

Patients with these risk variants can see their kidney function decline at an accelerated rate, often requiring dialysis a decade earlier than patients with other forms of chronic kidney disease. Currently, there are no approved therapies that specifically target the underlying genetic cause of AMKD, leaving physicians to manage symptoms with general kidney care, such as blood pressure medications.

“AMKD is a subset of chronic kidney disease with a large unmet need,” said Kate Bramham, M.B.B.S., Ph.D., a consultant nephrologist and member of the HORIZON trial's steering committee, in a statement. “A 30% uACR reduction is strongly correlated with a 10-year delay in progression to end-stage kidney disease and is widely recognized as a clinically meaningful threshold. MZE829 has the potential to be a truly differentiated treatment option.”

A Glimmer of Hope in the HORIZON Trial

Maze's MZE829 is an oral, small molecule drug designed as a dual-mechanism APOL1 inhibitor, aiming to block the toxic effects of the variant protein directly in the kidney's filtering cells, known as podocytes. The Phase 2 HORIZON trial was an open-label study that enrolled a broad population of 15 AMKD patients, including those with and without diabetes.

The topline data, based on 12 patients evaluated for efficacy at 12 weeks, showed a mean 35.6% reduction in proteinuria, a key indicator of kidney damage measured by the urinary albumin-to-creatinine ratio (uACR). Importantly, half of the patients achieved a reduction of 30% or more, hitting the critical benchmark for clinical significance. The drug was also reported to be well-tolerated, with no serious adverse events observed.

“We are pleased to show initial promising proof-of-concept for MZE829, an oral precision medicine that was designed to treat the underlying cause of AMKD,” said Harold Bernstein, M.D., Ph.D., president of R&D and chief medical officer of Maze. He noted the company's belief that the drug's dual-mechanism approach has the potential to address the significant unmet need in this patient population.

The results were particularly striking in a small subgroup of five patients with focal segmental glomerulosclerosis (FSGS), a severe form of AMKD. This group saw a mean uACR reduction of 61.8%, a figure that suggests the drug could be highly effective in the sickest patients.

A Jittery Market and a Formidable Rival

The impressive FSGS data, however, was not enough to quell investor anxiety. The market's skeptical reaction appears rooted in the competitive landscape, which is dominated by Vertex Pharmaceuticals and its own APOL1 inhibitor, inaxaplin. Vertex is significantly ahead in the race, with inaxaplin already in a large, global Phase 3 pivotal trial.

In 2021, Vertex presented its own Phase 2a data showing a 47.6% mean reduction in proteinuria in FSGS patients with AMKD. While Maze's 61.8% reduction in its FSGS subgroup appears superior on the surface, it comes from a much smaller and shorter study. The HORIZON trial's topline analysis included only 12 patients for efficacy, compared to a larger cohort in Vertex's initial studies. Investors may be concerned that the strong signal seen in a handful of FSGS patients may not translate to the broader, more commercially significant AMKD population, where MZE829's effect was more modest.

The stock's decline suggests that in the high-stakes world of biotech, being second to market requires demonstrating not just efficacy, but a clear “best-in-class” profile. For some investors, Maze's data, while positive, may not have cleared that high bar, especially when weighed against a smaller trial size and a competitor already nearing the finish line.

Maze's Path Forward: From Data to Pivotal Program

Despite the market's cold reception, Maze Therapeutics is forging ahead. The company announced its intention to continue enrollment in the HORIZON trial and advance MZE829 into a pivotal program, pending discussions with regulatory agencies. The company is betting that its unique dual-mechanism approach and the strong data in specific patient subgroups will ultimately carve out a significant role for MZE829.

Maze is also not a one-product company. Its strategy is built on its Compass™ platform, which uses human genetics to identify and validate novel drug targets. Its pipeline also includes MZE782, a candidate being developed for both chronic kidney disease and the rare metabolic disorder phenylketonuria (PKU), with Phase 2 trials expected to begin in 2026. The company appears financially well-positioned to pursue these goals, reporting $360 million in cash as of the end of 2025, which it projects will fund its operations into 2028. This financial runway provides the stability needed to navigate the lengthy and expensive process of late-stage clinical development and prove the ultimate value of its precision medicine approach.